The research performed in the Haibe-Kains Laboratory focuses on the integration of high-throughput data from various sources to simultaneously analyze multiple facets of diseases, with a particular emphasis on cancer. Dr. Haibe-Kains and his team are using publicly available genomic datasets and data generated through his collaboration to better understand the biology underlying diseases and to develop new predictive models in order to significantly improve disease management. Dr. Haibe-Kains's main contributions include several prognostic gene signatures in breast cancer, subtype classification models for ovarian and breast cancers, as well as genomic predictors of drug response in cancer cell lines.
Clin Cancer Res. 2018 Jul 03;:
Nucleic Acids Res. 2018 Jan 04;46(D1):D994-D1002
BJU Int. 2018 May 03;:
Publisher Correction: ZNF143 provides sequence specificity to secure chromatin interactions at gene promoters.
Nat Commun. 2018 Apr 10;9:16194
Eur J Cancer. 2018 Apr 06;95:38-51
Brief Bioinform. 2017 09 01;18(5):903
Radiomic Biomarkers to Refine Risk Models for Distant Metastasis in HPV-related Oropharyngeal Carcinoma.
Int J Radiat Oncol Biol Phys. 2018 Feb 01;:
Administration of Hypoxia-Activated Prodrug Evofosfamide after Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Colorectal Cancer.
Clin Cancer Res. 2018 Feb 23;:
Cancer Res. 2018 Feb 19;:
Author Correction: Gene isoforms as expression-based biomarkers predictive of drug response in vitro.
Nat Commun. 2018 Jan 09;9(1):166
Senior Scientist, Princess Margaret Cancer Centre
Assistant Professor, Department of Medical Biophysics, University of Toronto
Adjunct Assistant Professor, Department of Computer Science, University of Toronto
Ontario Institute for Cancer Research (OICR) Associate